Key Points
- EVP Ryan Savitz sold 114,367 shares on March 31 at an average price of $83.00, totaling about $9.49 million, as disclosed in an SEC filing.
- Wall Street sentiment is largely positive with one Strong Buy, eleven Buys and one Sell, a consensus target of $117.30, and individual price targets as high as $145.00.
- Dianthus is a clinical‑stage biotech developing DNTH103 (Phase 2), but recently reported a wider-than-expected loss (Q1 EPS of -$1.43 vs. -$0.97 estimate) and very negative margins and return on equity.
Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) EVP Ryan Savitz sold 114,367 shares of the stock in a transaction dated Tuesday, March 31st. The shares were sold at an average price of $83.00, for a total transaction of $9,492,461.00. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.
Dianthus Therapeutics Stock Performance
Shares of Dianthus Therapeutics stock opened at $86.00 on Friday. The stock has a market capitalization of $3.82 billion, a PE ratio of -20.98 and a beta of 1.22. Dianthus Therapeutics, Inc. has a 52-week low of $13.36 and a 52-week high of $88.49. The company has a 50-day simple moving average of $63.15 and a two-hundred day simple moving average of $47.62.
Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last posted its quarterly earnings results on Monday, March 9th. The company reported ($1.43) EPS for the quarter, missing analysts' consensus estimates of ($0.97) by ($0.46). The firm had revenue of $0.57 million for the quarter, compared to analysts' expectations of $0.40 million. Dianthus Therapeutics had a negative net margin of 7,973.33% and a negative return on equity of 38.85%. As a group, equities research analysts forecast that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current fiscal year.
Institutional Investors Weigh In On Dianthus Therapeutics
A number of large investors have recently added to or reduced their stakes in DNTH. Wellington Management Group LLP raised its stake in Dianthus Therapeutics by 3,366.9% during the 3rd quarter. Wellington Management Group LLP now owns 2,577,662 shares of the company's stock valued at $101,431,000 after buying an additional 2,503,311 shares during the last quarter. Vestal Point Capital LP grew its holdings in shares of Dianthus Therapeutics by 88.2% in the second quarter. Vestal Point Capital LP now owns 3,200,000 shares of the company's stock worth $59,616,000 after acquiring an additional 1,499,931 shares during the period. State Street Corp grew its holdings in shares of Dianthus Therapeutics by 124.7% in the fourth quarter. State Street Corp now owns 1,507,619 shares of the company's stock worth $62,129,000 after acquiring an additional 836,571 shares during the period. Braidwell LP purchased a new stake in Dianthus Therapeutics during the third quarter valued at $32,859,000. Finally, Polar Capital Holdings Plc bought a new position in Dianthus Therapeutics in the third quarter valued at about $29,434,000. Institutional investors own 47.53% of the company's stock.
Wall Street Analyst Weigh In
DNTH has been the topic of several recent analyst reports. Wells Fargo & Company initiated coverage on Dianthus Therapeutics in a research note on Thursday, March 19th. They set an "overweight" rating and a $135.00 target price on the stock. Wedbush upped their price target on Dianthus Therapeutics from $55.00 to $80.00 and gave the company an "outperform" rating in a report on Tuesday, March 10th. Oppenheimer increased their price objective on Dianthus Therapeutics to $145.00 and gave the company an "outperform" rating in a research report on Monday, March 9th. Robert W. Baird lifted their price objective on Dianthus Therapeutics from $67.00 to $132.00 and gave the stock an "outperform" rating in a report on Tuesday, March 10th. Finally, TD Cowen reissued a "buy" rating on shares of Dianthus Therapeutics in a research report on Monday, March 9th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $117.30.
View Our Latest Report on Dianthus Therapeutics
Dianthus Therapeutics Company Profile
(
Get Free Report)
Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
